Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Dusseldorf - Delayed Quote EUR

Jazz Pharmaceuticals PLC (J7Z.DU)

Compare
140.00
+7.00
+(5.26%)
At close: February 27 at 4:00:10 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
4,068,950
4,068,950
3,834,204
3,659,374
3,094,238
Cost of Revenue
445,713
445,713
435,577
540,517
440,760
Gross Profit
3,623,237
3,623,237
3,398,627
3,118,857
2,653,478
Operating Expense
2,896,607
2,896,607
2,801,047
2,606,589
2,483,200
Operating Income
726,630
726,630
597,580
512,268
170,278
Net Non Operating Interest Income Expense
-238,097
-238,097
-289,438
-288,242
-278,766
Other Income Expense
-18,182
-18,182
-10,213
-596,810
-4,350
Pretax Income
470,351
470,351
297,929
-372,784
-112,838
Tax Provision
-91,429
-91,429
-119,912
-158,645
216,116
Earnings from Equity Interest Net of Tax
-1,660
-1,660
-3,009
-9,921
-714
Net Income Common Stockholders
560,120
560,120
414,832
-224,060
-329,668
Average Dilution Earnings
10,762
10,762
24,876
--
--
Diluted NI Available to Com Stockholders
570,882
570,882
439,708
-224,060
-329,668
Basic EPS
7.43
9.06
6.55
-3.58
-5.52
Diluted EPS
7.06
8.65
6.10
-3.58
-5.52
Basic Average Shares
62,348.25
61,838
63,291
62,539
59,694
Diluted Average Shares
68,049.75
66,007
72,066
62,539
59,694
Total Operating Income as Reported
716,630
716,630
578,580
-65,528
170,278
Total Expenses
3,342,320
3,342,320
3,236,624
3,147,106
2,923,960
Net Income from Continuing & Discontinued Operation
560,120
560,120
414,832
-224,060
-329,668
Normalized Income
574,483.78
574,483.78
422,900.27
247,419.90
-326,492.50
Interest Expense
238,097
238,097
289,438
288,242
278,766
Net Interest Income
-238,097
-238,097
-289,438
-288,242
-278,766
EBIT
708,448
708,448
587,367
-84,542
165,928
EBITDA
1,368,515
1,368,515
1,226,063
544,929
718,411
Reconciled Cost of Revenue
412,959
412,959
405,165
510,215
414,046
Reconciled Depreciation
660,067
660,067
638,696
629,471
552,483
Net Income from Continuing Operation Net Minority Interest
560,120
560,120
414,832
-224,060
-329,668
Total Unusual Items Excluding Goodwill
-18,182
-18,182
-10,213
-596,810
-4,350
Total Unusual Items
-18,182
-18,182
-10,213
-596,810
-4,350
Normalized EBITDA
1,386,697
1,386,697
1,236,276
1,141,739
722,761
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-3,818.22
-3,818.22
-2,144.73
-125,330.10
-1,174.50
12/31/2021 - 2/3/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MAGLE.ST Magle Chemoswed Holding AB (publ)
31.00
-4.32%
 
NV3P.F NanoViricides, Inc.
1.1800
+4.42%
 
C4X.F Valerio Therapeutics Société anonyme
0.0511
-0.39%
 
HQ1.MU Oruka Therapeutics Inc. R
10.20
-0.97%
 
RGO.DU Regeneron Pharmaceuticals Inc
670.80
-1.93%
 
MOC.WA Molecure S.A.
8.99
-0.11%
 
PH4.F CStone Pharmaceuticals
0.4500
+4.17%
 
BSSP Baseline Productions, Inc.
0.0001
0.00%
 
ARDX.MX Ardelyx, Inc.
105.50
0.00%
 
AREC.L Arecor Therapeutics plc
50.00
-2.91%